Skip to main content
Figure 1 | Molecular Pain

Figure 1

From: PI3K mediated activation of GSK-3β reduces at-level primary afferent growth responses associated with excitotoxic spinal cord injury dysesthesias

Figure 1

QUIS-injection increased GSK-3βP in the spinal cord dorsal horn and DRG ipsilateral at and just caudal to the level of injury compared to saline-injected (sham) 14 days following injury. a Representative immunofluorescence image of GSK-3βP in the superficial dorsal horn (L1) and DRG (L1, ipsilateral site of injection) shows increased GSK-3β phosphorylation (inhibition) following QUIS-injection compared to sham operated controls (Sham, n = 5, QUIS n = 6). b, c Bar graphs represent mean densitometric values of GSK-3βP in spinal cord (b) and DRG (c). d, e Western blot analysis of the SC and DRG taken from the level of the lesion shows that GSK-3βP expression was significantly increased 14 days following QUIS-injection (Sham, n = 3 and QUIS, n = 3). Error bars ± SEM (*p < 0.05). Scale bars spinal cord 100 μm, DRG 50 μm.

Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us